Evaluation of IL-35 and IL-39 in Rheumatoid Arthritis

DOI: https://doi.org/10.32007/jfacmedbagdad.6431963

Raghad Hatem Omran* BSc
Zahra’a A. Ahmed* PhD
Aymen A. Alrawi** MBChB, DMR

Abstract

Background: Cytokines have an essential contribution to the inflammatory response and the development of chronic inflammation. Therefore, they have a pivotal role in the pathogenesis of rheumatoid arthritis. Interleukins are closely related to rheumatoid arthritis, and the exact role of some interleukins in the pathogenesis of rheumatoid arthritis is not yet known, such as IL-35, which has suppressive activity, particularly in cancer and autoimmune diseases. As well as IL-39, which promotes inflammatory responses and the activation of immune cells. Therefore, the aim of current study was to evaluate the levels of interleukins 35 and 39 and their ratio in rheumatoid arthritis patients in Iraq.

Methods: ELISA was used to measure the levels of interleukins in the blood of 56 patients with rheumatoid arthritis and 44 healthy volunteers who were enrolled in the study from November 2021 to March 2022. The level of interleukins was statistically analyzed using the computer program Statistical Package for Social Sciences (version 14).

Results: The serum levels of IL-39 in the rheumatoid arthritis patient groups were significantly higher than in the control group (p = 0.043). In contrast, the level of IL-35 was slightly higher in rheumatoid arthritis patients but not by significantly different values (p = 0.055). The cytokine ratio, IL-39/IL-35, was the same for the groups, and there were no significant differences when comparing patients to controls (14.30 ± 1.47 vs. 13.18 ± 0.71). In addition, IL-39 concentration levels were significantly higher in rheumatoid arthritis patients under therapy than in rheumatoid arthritis patients with a first diagnosis and without therapy.

Conclusion: Rheumatoid arthritis is associated with an increased level of IL-35 and IL-39, so assessment of the levels of these cytokines may be helpful in confirming rheumatoid arthritis activity.

Keywords: Autoimmunity, Cytokines, IL-35, IL-39, Rheumatoid arthritis.

Introduction:

RA is a chronic autoimmune inflammatory disease that causes progressive destruction of bone and cartilage. The development of autoimmune diseases such as RA and systemic lupus erythematosus (SLE) can be caused by either a decrease in anti-inflammatory cytokines or an increase in pro-inflammatory cytokines[1] [2]. This imbalance between pro- and anti-inflammatory cytokines may be an underlying element in disease progression via inflammation and the loss of articular cartilage [3]. Members of the IL-12 cytokine family have a crucial role in regulating innate and adaptive immunity and also in the management of inflammatory diseases [4]. Interleukin-35 and interleukin-39 (IL-35 and IL-39) are members of the IL-12 family and play significant roles in several autoimmune diseases. In addition, they have been researched as potential therapeutic targets in the management of several autoimmune diseases [5]. IL-35 is secreted primarily by regulatory T cells (Treg) and has anti-inflammatory and immunosuppressive properties. It can enhance Treg proliferation and inhibit T helper-17 (Th17) cell differentiation. Therefore, by maintaining the balance between Th17 and Tregs cells, IL-35 is crucial to the progression of RA. IL-35 is closely related to the incidence of inflammation in infections and autoimmune diseases [6]. IL-39 is a new member of the IL-12 cytokine family, which was recently identified. It has been shown that IL-39 plays a role in SLE pathogenesis in vivo and induces differentiation and activation of neutrophils. B cells express IL-39 more frequently by secreting the B-cell stimulatory factor [7]. IL-35 is strictly anti-inflammatory, while IL-39 is relatively less well-characterized, but accumulating evidence points to its pro-inflammatory actions. Therefore, the aim of current study was to evaluate the levels of interleukins 35 and 39 and their ratio in RA patients in Iraq.

Patients and methods:

Patients
A total of 56 patients with RA were referred to the Rheumatology Consultation Clinic/Baghdad Teaching Hospital in Baghdad for diagnosis and treatment from...
November 2021 to March 2022 and were enrolled in this study (approval was obtained from the Ministry of Health No. 37776 on 25/10/2021). Also, 44 healthy volunteers were used as a control sample and were matched with patients based on their gender, age, and ethnicity.

**Diagnosis of RA**

After a clinical examination of the patients by the hospital medical staff, we performed an erythrocyte sedimentation rate (ESR) test (using the standard Westergren method), an anti-cyclic citrullinated peptide (Anti-CCP) test (Hotgen, China), a C-reactive protein (CRP) and rheumatoid factors (RF) tests (SPINREACT, Spain), on the blood samples. According to the laboratory tests and information sheet for each subject, the samples were divided into RA and other rheumatic diseases (excluded).

**Measurement of IL-35 and IL-39 Serum Levels**

The levels of IL-35 and IL-39 were measured in the blood of RA patients and healthy controls using sandwich ELISA kits from Bioassay Technology Laboratory in China. These kits were designed for quantitative measurement of human cytokines based on the same principles.

**Statistical analysis**

Statistical analysis was performed using SPSS (version 14), and all data was reported as mean ± standard error (SE). ANOVA (one-way analysis of variance) was used to evaluate differences between groups, and a T-test was used to compare cytokine levels between groups. P<0.05 was used to indicate a statistically significant difference.

**Result**

The results showed a high prevalence of RA in females compared to males (87.5% vs. 12.5%, respectively), and the age (Mean ± Standard Deviation) of RA patients was 50.107 ± 12.422 years. When distributing RA patients according to age groups, the largest proportion of RA patients (88%) were older than 40 years. In addition, the results of this study showed that the serum level of IL-39 in RA patients compared with the control group was (196.392 ± 26.532 vs. 132.790 ± 9.227 ng/L), while IL-35 was (160.018 ± 2.074 vs. 11.059 ± 0.383 ng/ml), as shown in table (1). A significantly increased in IL-39 concentration was observed in RA patients compared to controls, but the increment in IL-35 didn’t show a statistically significant difference (P = 0.055). The cytokine ratios (IL-39/IL-35) were the same for the groups, and there were no significant differences when comparing patients to controls, (14.30 ± 1.47 vs. 13.18 ± 0.71).

**Table 1: Serum levels of IL-35 and IL-39 in RA patients and healthy controls**

<table>
<thead>
<tr>
<th>Cytokines</th>
<th>Mean ± Standard Error</th>
<th>t-test t</th>
<th>P- values</th>
<th>95% CI</th>
<th>Controls (n=44)</th>
<th>Patients (n=56)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-35 (ng/ml)</td>
<td>11.059 ± 0.833</td>
<td>16.018 ± 2.074</td>
<td>1.940</td>
<td>0.055</td>
<td>0.116 -</td>
<td>10.034</td>
</tr>
<tr>
<td>IL-39 (ng/ml)</td>
<td>132.790 ± 9.227</td>
<td>196.392 ± 26.532</td>
<td>0.436</td>
<td>0.668</td>
<td>0.156 -</td>
<td>1.385</td>
</tr>
</tbody>
</table>

Regarding therapy status, the results of the present study showed that 46 (82.1%) of RA patients received therapy, while 10 (17.9%) of RA patients did not receive any therapy (diagnosis onset). When studying the value of cytokine levels in these two types of therapy in RA patients, the results showed elevated serum levels of cytokines in patients under therapy compared to those not under therapy, with significant differences in IL-39 (211.594 ± 32.210 vs. 134.064 ± 22.346 ng/L), while there are no significant differences in IL-35 (17.044 ± 2.484 vs. 11.299 ± 1.504 ng/ml), figure (1).

**Discussion**

Pro-inflammatory cytokines are crucial in the processes that lead to inflammation, joint destruction, comorbidities associated with RA, and many other disorders brought on by an uncontrolled self-directed immune response [8] [9]. IL-39 is the modern member of the interleukin-12 cytokine family, which is important in autoimmune diseases, including SLE [10]. A significantly elevated IL-39 level was observed in RA patients in the current study, with a significant difference when compared to control. In studies conducted by [11] and [12], serum levels of IL39 were found to be significantly higher in patients with myocardial infarction disease and neuromyelitis disorders. Furthermore, it was observed that IL-39 in lupus-like mice produces an immune-pathogenic impact by promoting the inflammatory response. IL-39 increased the levels of IFN-γ, TNF-α, and IL-17, thus eliciting a pro-inflammatory state as well as demonstrating the potential to regulate the immune system. As a result, targeting IL-39 may provide a successful treatment for autoimmune diseases [13, 14]. Anti-inflammatory cytokines (for example Transforming growth factor beta (TGF-β), IL-4, IL-10, and IL-13) effectively prevent autoimmune disease, either by affecting innate cellular immunity, such as deviating macrophage polarization, or by
تقييم IL-35 و IL-39 في التهاب المفاصل الروماتويدي

رغد حاتم عمران

الخلفية:
الحركيات الخلوية لها مساهمة أساسية في الاستجابة الالتهابية وتطور الالتهاب المزمن. لذلك لها دور محوري في التسبب في التهاب المفاصل الروماتويدي. ترتبط الببتيدات ارتباطًا بالتهاب المفاصل الروماتويدي، والدور الفعال لبعض الببتيدات في التسبب في التهاب المفاصل الروماتويدي غير معروف حتى الآن مثل IL-35، IL-39، IL-41، وتعزز ارتباط الببتيدات التشريحي الخلايا المناعية. لذلك كان الهدف من الدراسة الحالية هو تقييم مستويات الببتيدات ونسبتها في مرضى التهاب المفاصل الروماتويدي في العراق.

المرضى والطرق:
تم استخدام مقايسة الممتز المناعي المرتبط بالإنزيم (ELISA) لقياس مستويات الببتيدات في دم 56 مريضًا مصابًا بالتهاب المفاصل الروماتويدي و44 متطوعًا سليمًا تم تسجيلهم في الدراسة من تشرين الثاني 2021 إلى أذار 2022. تم تحليل مستوى الببتيدات إحصائيًا باستخدام برنامج SPSS (الإصدار 14).

النتائج:
كانت مستويات IL-35 في مصل الدم في مجموعات مرضى التهاب المفاصل الروماتويدي أعلى بكثير مما كانت عليه في مجموعات التحكم. كان مستوي IL-35 أعلى قليلاً في مرضى التهاب المفاصل الروماتويدي ولكن ليس يتميز بشكل كبير (P = 0.043). من ناحية أخرى، كانت نسبة الحركيات الخلوية IL-35 / IL-39 في المرضى بالتهاب المفاصل الروماتويدي مشابهة للكميات المشابهة في المرضى السليمين. بالإضافة إلى ذلك، كانت مستويات تركيز IL-39 أعلى بشكل ملحوظ في مرضى التهاب المفاصل الروماتويدي 

الاستنتاج:
إرتفاع مستويات الببتيد IL-35 و IL-39، مما يشير إلى أن هذه الحركيات الخلوية قد تكون مسؤولة عن نشاط التهاب المفاصل الروماتويدي. وتزيد من حساسية التشخيص الأول وبدون علاج.

الكلمات المفتاحية: المناعة الذاتية، الحركيات الخلوية، IL-35، IL-39، التهاب المفاصل الروماتويدي.